Indoco Remedies (INDOCO) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 saw mixed results with strong growth in key brands like Cyclopam, Cital, and Karvol Plus, but slow revival in anti-infective and respiratory portfolios and negative growth in Febrex Plus dampened performance.

• Unaudited standalone and consolidated financial results for the quarter ended 30th June 2024 were approved, with statutory auditors issuing an unmodified review opinion.

• The quarter reflects ongoing strategic transitions, including licensing, US market expansion, and selective OTC product focus.

• Received final ANDA approval for pregabalin capsules and tentative approval for canagliflozin/metformin from USFDA; successful USFDA inspections at API Kilo plant and Analytical Solutions lab with zero observations.

• Launched new products including FosHS for UTIs, Hylupro, Brimigan, Olarchek eye drops, Kidodent mouthwash, and Calaid XT tablets; Sensodent K variants entered OTC market and won advertising awards.

Financial highlights

• Net revenues for Q1 FY25 at INR 3,942 million, down 4.6% YoY from INR 4,132 million.

• Standalone revenue from operations for Q1 FY25 was ₹39,422 lakhs, down from ₹41,319 lakhs in Q1 FY24 and ₹43,514 lakhs in Q4 FY24.

• Consolidated revenue from operations for Q1 FY25 was ₹42,429 lakhs, down from ₹41,681 lakhs in Q1 FY24 and ₹43,908 lakhs in Q4 FY24.

• EBITDA margin for the quarter was 13.1% (INR 516 million), down from 15.2% (INR 629 million) YoY.

• Net profit margin at 3.8% (INR 150 million) vs. 6.3% (INR 259 million) YoY; standalone profit after tax for Q1 FY25 was ₹1,495 lakhs, and consolidated profit after tax was ₹182 lakhs.

Outlook and guidance

• Plant refurbishments and automation expected to complete by Q2, with normalized US supply and margin recovery from Q3.

• Europe business expected to deliver 20% CAGR over five years; US business to see 30% CAGR from FY26 as supply constraints ease.

• Emerging markets projected to grow at 18-20% CAGR over the next few years.

• EBITDA margin guidance of minimum 15% for FY25, with Q3 and Q4 expected to be stronger.

• Management highlights ongoing strategic transitions and expresses confidence in long-term gains from current initiatives.